Recurrent Verrucous Carcinoma of the Larynx Completed Phase 1 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0029506 (Recurrent Verrucous Carcinoma of the Larynx)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00023959Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerTreatment